CD73

488,00 plus VAT

#DIA-KK3
• academic pricing available •
Anti-CD73 (HU) from Mouse (clone KK3) – 500 µl
Category:

Description

Cat.No.DIA-KK3
SpecificityCD73
Species ReactivityHuman
Host SpeciesMouse
IsotypeIgG2b/κ
CloneCD73
Application
Immunohistochemistry (IHC),
Formalin-fixed Paraffin-embedded sections (FFPE)
Western Blot
Conjugationunconjugated
DilutionIHC 1:100-1:200
Format
Lyophilisate, 20µg
Antibody purified (from culture supernatant)
Quantity500µl
Positive controlTonsil
PresentationPBS pH 7.4, 2%BSA, 0.05%NaN3
Intended UseResearch Use Only
Manufacturer / BrandONCOdianova
CD73 IHC-Gallery
IHC-figures and legends on CD73 detection in different tumors.

Reactivity

Clone KK3 has been developed and validated specifically for the immunohistochemical (IHC) detection of CD73 in routine fixed human tissue specimen (FFPE). The CD73-adenosine axis has emerged as one of the most promising therapeutic targets in immuno-oncology. An immunosuppressive role of CD73-adenosine in cancer has been demonstrated by several labs independently. Immunohistochemical (IHC) application of monoclonal antibody KK3 may help to develop a better understanding of cell- and tissue- specific roles of CD73. Moreover, it will be important to differentiate patient populations for adenosine-targeting agents. Immunohistochemical (IHC) application of anti-CD73 clone KK3 may provide valuable information for identification of patients that will benefit from novel therapies.

IHC protocols

Staining protocols for anti-human CD73 antibody clone KK3
(will be updated continuously)
Manual stain with autoclave
  • TRIS-EDTA-Citrat buffer (TEC-buffer, Dako): 121°C / 5 min / pH7,8
  • Incubation primary antibody: 60 min / 37°C (Dilution: 1:150)
  • Envision HRP rabbit/mouse: 30 min / 37°C

References

References

  1. Leone RD et al. Targeting adenosine for cancer immunotherapy. J Immunother Cancer (2018) 159(6):57.
  2. Allard D et al. Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett. (2018) 205:31–39.
  3. Abtonioli L. et al. Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment. Oncoimmunology (2016) 5(9):e1216292.
  4. Allard B et al. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. (2016) 29:7–16
  5. Jin D et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. (2010) 70:2245–2255.

You may also like…

Menu